氟苯尼考在欧洲鳗鲡体内的药物代谢动力学的研究

应用反相高效液相色谱法对口灌和肌肉注射氟苯尼考在欧洲鳗鲡(Anguilla anguilla)体内的代谢规律进行了研究.按100 mg·kg-1口灌给药后血浆、肌肉、肝脏、肾脏中氟苯尼考浓度的达峰时间分别为2h、6h、0.5h、1h,以后开始缓慢下降,给药2d后血浆、肌肉、肝脏、肾脏中的氟苯尼考浓度分别为4.209μg·mL-1、0.792μg·g-1、0.493μg·g-1、1.448μg·g-1,给药3d后血浆中的氟苯尼考浓度分别为0.0836μg·mL-1,肌肉、肝脏、肾脏中的氟苯尼考浓度均未检出;按100mg·kg-1肌肉注射给药后血浆中氟苯尼考浓度达峰时间为0.5h,以后开始缓慢下降,给药5d后血浆中的氟苯尼考浓度为0.1151μg·mL-1,给药10d后血浆中的氟苯尼考浓度未检出.口灌氟苯尼考在欧洲鳗鲡体内血浆、肌肉、肝脏、肾脏中分布可用开放性二室模型来描述,口灌给药的血浆、肌肉、肝脏、肾脏中的消除半衰期(T1/2β)分别为27.939h、18.844h、11.83h、36.87h;肌肉注射氟苯尼考在欧洲鳗鲡体内血浆、肌肉、肝脏、肾脏中分布可用开放性一室模型来描述,肌肉注射给药的血浆中的消除半衰期(T1/2β)为37.52h.     

恩诺沙星及其代谢物环丙沙星在欧洲鳗鲡体内的代谢动力学

采用高效液相色谱法,研究药饵口灌给药途径下,恩诺沙星及其代谢物环丙沙星在欧洲鳗鲡(Anguilla anguilla)体内的药代动力学。欧洲鳗鲡口灌给药恩诺沙星10 mg/kg后,其血浆、肌肉和肝脏中药物时量曲线关系符合一级吸收的二室开放动力学模型。恩诺沙星在欧洲鳗鲡不同组织中分布较广,血浆、肌肉和肝脏的Vd分别为6.362 L/kg、8.081 L/kg和15.870 L/kg;恩诺沙星在鳗鲡体内消除较慢,在血浆、肌肉和肝脏中的消除半衰期(tβ1/2)分别为161.10 h、333.21 h和611.26 h,总体清除率(CLs)分别为27.4 mL/(kg.h)、16.8 g/(kg.h)和18.0 g/(kg.h)。代谢物环丙沙星在鳗鲡血浆、肌肉和肝脏中药物水平的变化趋势与恩诺沙星基本相似,呈现出多峰现象,但3种组织中环丙沙星出现第一个药峰时间分别为给药后第24小时、24小时和12小时,3种组织中环丙沙星峰值水平肝脏中最高、肌肉中次之、血浆中最低,环丙沙星在肌肉和肝脏中的消除速率比较缓慢。鉴于恩诺沙星和其代谢物环丙沙星在欧洲鳗鲡体内消除较慢,建议养成阶段使用其他药物。     

噁喹酸在凡纳滨对虾体内药动学和对弧菌的体外药效

采用高效液相色谱法,研究了复方噁喹酸粉药饵投喂在凡纳滨对虾体内药动学和组织中消除规律,同时检测了噁喹酸对对虾源弧菌的最小抑菌浓度(MIC),建立了药动/药效(PK/PD)关系,提出了用药方案和休药期建议。结果显示,复方噁喹酸粉拌饵投喂给药,噁喹酸给药剂量为30 mg/kg(体质量),凡纳滨对虾血浆噁喹酸浓度—时间关系曲线均符合一级吸收二室开放动力学模型。血淋巴中噁喹酸达峰浓度(Cmax)、达峰时间(Tmax)、曲线下面积(AUC0-24)和消除半衰期(t1/2z)分别为14.70 mg/L、2 h、244.6 mg/(L·h)和18.56 h;肌肉、肝胰腺和鳃的峰浓度(Cmax)分别为4.11、17.20和7.01 mg/kg,消除半衰期(t1/2z)分别为10.71、12.31和16.75 h。噁喹酸对132株弧菌的MIC主要分布在0.15~1.25μg/m L,MIC50和MIC90分别为0.62和1.25μg/m L。PK/PD相互关系参数Cmax/MIC90和AUC0-24/MIC90分别为11.76和195.7。研究表明,噁喹酸以30 mg/(kg体质量)剂量药饵给药,凡纳滨对虾能很好地吸收噁喹酸,可以有效地防治弧菌引起的细菌性疾病。     

诺氟沙星在日本鳗鲡体内的代谢动力学及残留消除规律

为研究诺氟沙星(NFX)在鳗鲡体内的代谢和消除规律,以超高效液相色谱-串联质谱法测定日本鳗鲡在混饲口灌后血液和组织中NFX的含量变化,并进行药动学分析。结果表明,NFX以30 mg/kg的剂量单次混饲口灌日本鳗鲡后,吸收分布迅速,达峰时间(T_(max))、吸收(T_(1/2Ka))和分布半衰期(T_(1/2α))分别为3.000、1.012和1.570 h;NFX在鳗鲡体内消除较快,消除半衰期(T_(1/2β))为15.267 h,总清除率(CL)为1.315 L/(h·kg)。此外,峰浓度(C_(max))为1.273 mg/L,药时曲线下面积(AUC_(0~∞))为22.670 mg/(L·h)。NFX以30 mg/kg的剂量连续3 d混饲口灌日本鳗鲡后,在肌肉、肝脏、肾脏和血浆中的消除速率常数分别为0.144、0.125、0.102和0.093 1/d。根据WT1.4计算的理论休药期(WDT)分别为肌肉22.97 d,肝脏21.30 d,肾脏33.40 d,血浆18.29 d。本研究结果为诺氟沙星在水产动物中的实际应用提供理论依据。     

两种给药途径土霉素残留在鲫鱼体内的消除规律

探讨了在肌肉注射和口灌给药方式下土霉素残留在鲫鱼组织内的消除情况。结果表明: 鲫鱼肌肉注射和口灌给药后土霉素在体内的最大浓度依次是: 肌肉 4 636mg/kg和 2 869mg/kg, 血液 5 467mg/kg和 3 112mg/kg, 肝脏 7 165mg/kg和 5 086mg/kg, 肾脏 8 308mg/kg和 5 017mg/kg; 肌肉注射第 288h时除肾脏中的土霉素浓度仍然高达 0 375mg/kg, 其他组织中已经检测不到土霉素的存在, 而口灌给药第 288h时肌肉、血液、肝脏、肾脏中土霉素的浓度依次为: 0 133mg/kg, 0 237mg/kg, 0 272mg/kg, 0 272mg/kg。因此, 在 (10±1)℃水温条件下, 以剂量 50mg/kg鱼体重单次给药, 肌肉注射各组织内的药物浓度比口灌给药高, 口灌给药消除速度比肌肉注射慢。本次实验结果建议在 (10±1)℃以上水温条件下, 无论肌肉注射还是口灌给药, 建议第 12天以后捕鱼食用是安全的。     

单剂量口灌阿维菌素在草鱼体内的药动学及残留研究

按0.1 mg/kg的剂量给草鱼(Ctenopharyngodon idellus)灌服阿维菌素,用高效液相色谱法检测用药后不同时间的血浆、肌肉和肝脏中的药物浓度,然后用3P97药代动力学软件处理药时数据,对药物在草鱼体内药动学及组织残留进行研究.结果表明:单剂量口灌阿维菌素在草鱼血浆中主要药动学参数为:AUC 1 6...     

盐酸氯苯胍在眼斑拟石首鱼体内的药代动力学和残留消除规律研究

在水温(28±2)℃、盐度28条件下,采用30mg/kg的剂量口灌法,用HPLC-MS/MS检测研究了盐酸氯苯胍在体质量为(350.15±5.18)g的眼斑拟石首鱼体内的药代动力学和残留消除规律。结果显示,单剂量口灌给药后,眼斑拟石首鱼血浆中盐酸氯苯胍的药时数据符合一级吸收二室模型,药物在血浆中的达峰时间、血药质量浓度峰值、药时曲线下面积和消除半衰期分别为2.39h、958.78μg/L、33 247.57μg/(L·h)和19.24h;盐酸氯苯胍在肌肉、肝脏和肾脏的血药含量峰值分别为156.72、227.68μg/kg和553.44μg/kg,达峰时间分别为2.0、1.5、2.0h;药时曲线下面积分别4664.04、4897.74、17 228.19μg/(kg·h);消除半衰期分别为19.68、24.33、22.81h。按30mg/kg剂量连续5d口灌给药后,鱼血浆、肌肉、肝脏、肾脏中的药物消除半衰期(t1/2)分别为24.46、35.39、39.60、33.94h。若以10μg/kg为最高残留限量,肌肉作为食用靶组织,在本试验条件下,建议休药期不少于7d。     

磺胺甲基异噁唑在大菱鲆体内的代谢动力学研究

采用高效液相色谱法测定血浆、肌肉和肝脏中的磺胺甲基异噁唑含量,通过3P97药动学软件对磺胺甲基异噁唑在大菱鲆体内的药代动力学规律进行了分析研究。研究结果表明,在（11±1）℃水温条件下,单次口灌100mg／kg磺胺甲基异噁唑（SMZ）,SMZ在大菱鲆肌肉、肝脏和血浆中的代谢过程均符合一级吸收一室模型。大菱鲆肌肉、肝脏和血浆中药物浓度分别在给药后11．89、10．53和4.87h达到最大值,Cmax分别为21．52、5．35和44．07mg／kg,给药后5、6d和72h含量低于最大残留限量（0．1mg／kg）,18、24和10d后SMZ未检出（〈0．01mg／kg）。     

伊维菌素在鲫体内的药代动力学

以0.4 mg/kg的给药剂量进行口灌和肌肉注射给药,研究伊维菌素(IVM)在鲫体内的药代动力学。两种给药方式下,鲫组织中的IVM药—时曲线大都呈现多峰现象。肌肉注射给药后,药动学统计矩参数为Cmax=0.445 mg/L、Tmax=48 h、t1/2z=524.2 h、MRT(0-∞)=788 h、AUC(0-∞)=289.2(mg/L).h;口灌给药后,药动学统计矩参数为Cmax=0.264 mg/L、Tmax=8 h、t1/2z=153.9h、MRT(0-∞)=269.78 h、AUC(0-∞)=83.77(mg/L).h。两种给药方式相比,口灌组鲫对药物的吸收和清除均较快,而肌肉注射组鲫各组织中的药物浓度高,AUC值也较大。两种给药方式下,IVM在鲫各组织中AUC(0-600)值呈现相同的排列顺序,由大到小分别为性腺、血液、肾脏、肝胰脏、肌肉。IVM在鲫性腺和肾脏中均具有一定的蓄积作用,其主要表现为药物浓度高,MRT值大,且清除率低于血药的清除率,其中卵巢的积蓄作用最为明显。25℃的水温条件下,肌肉注射给药后,鲫休药期应不低于25 d;口灌给药后,鲫的休药期应不低于15 d。休药期与水温条件和给药剂量有关,因此在养殖生产过程中的休药期要根据实际情况适当调整。     

溴氰菊酯在欧洲鳗鲡体内药代动力学研究

在试验水温(25±1)℃时,按100μg·L-1的剂量给欧洲鳗鲡药浴溴氰菊酯36h后,采用气相色谱法测定血浆和肌肉中的药物浓度,研究了溴氰菊酯在欧洲鳗鲡体内的代谢及消除规律.采用DAS自动化药动学分析程序对数据进行分析.结果表明:欧洲鳗鲡血浆和肌肉中溴氰菊酯经时过程均符合一级吸收一室开放模型,血浆中主要药动学参数为:T1/2k为148.296h,Cmax为18.446μg·L-1,Tmax为14.7h.肌肉中主要药动学参数为:T1/2k为386.912h,Cmax为44.291μg·kg-1,Tmax为49.6h.肌肉作为可食性组织,且消除较慢,因此选取肌肉组织作为残留检测的靶组织,以10μg·kg-1为最高残留限量,在本试验条件下,建议休药期不低于9d.     

土霉素在奥尼罗非鱼体内的药动学研究

在(21±1)℃的水温条件下,以50 mg/kg的单剂量,分别给奥尼罗非鱼(Oreochromis aureus×O.niloticus)水剂口灌和混饲口灌土霉素,用高效液相色谱法(HPLC)检测给药后各个时间点的血药浓度。结果显示:最低检测限为0.005μg/mL,线性范围为0.005~4μg/mL。水剂口灌组和混饲口灌组的药时数据均符合具时滞的二室开放动力学模型,水剂口灌组的动力学方程为:Ct=0.231e-0.028(t-0.010)+0.353e-0.011(t-0.010)-0.584e-0.468(t-0.010),混饲口灌组动力学方程:Ct=0.839e-0.057(t-0.459)+0.442e-0.013(t-0.459)-1.281e-0.282(t-0.459)。水剂口灌组及混饲口灌组主要药动学参数分别为:吸收半衰期(t1/2ka)为1.481 h,2.458 h;分布半衰期(t1/2α)为24.834 h,12.193 h;消除半衰期(t1/2β)为60.312 h,51.533 h;达峰时间(Tmax)为7.230 h,8.221 h;最大血药浓度(Cmax)为0.494μg/mL,0.796μg/mL;血药浓度-时间曲线下面积(AUC)=37.74μg.h/mL,43.075μg.h/mL。这些参数表明,水剂口灌比混饲口灌吸收快,分布和消除慢,在血液中达到峰浓度的时间更短,但峰浓度值比混饲口灌低。     

盐酸诺氟沙星在奥尼罗非鱼体内的生物利用度研究

采用高效液相色谱法分别测定静脉注射和混饲口灌奥尼罗非鱼(Oreochromis aureus×O.niloticus)盐酸诺氟沙星后鱼体血液中该药含量变化,用3P97药动学软件分析药动学参数,计算生物利用度.结果表明,在(25±1)℃水温下,以10 mg/kg剂量对奥尼罗非鱼静脉注射和混饲口灌盐酸诺氟沙星,静脉注射药时...     

盐酸诺氟沙星在奥尼罗非鱼体内的药动学研究

按照鱼的体重,以10 mg/kg的单剂量,分别给奥尼罗非鱼(Oreochromis aureus×O.niloticus)水剂口灌和混饲口灌盐酸诺氟沙星,用高效液相色谱法(HPLC)检测给药后各个时间点的血药浓度。结果显示:水剂口灌组和混饲口灌组的药时数据符合开放性二室模型,水剂口灌组药物的吸收、消除都明显快于混饲组,水剂口灌组主要药动学参数为:t1/2ka=0.269 h,t1/2α=0.588 h,t1/2β=16.42 h,Tmax=0.745 h,Cmax=0.123μg/mL,AUC=1.83 h;混饲口灌组主要药代动力学参数:t1/2ka=0.428 h,t1/2α=1.85 h,t1/2β=21.77 h,Tmax=1.63 h,Cmax=0.099μg/mL,AUC=2.42 h。     

三聚氰胺在斑点叉尾鮰体内的残留及代谢规律研究

(21±1)℃水温条件下,研究了三聚氰胺在斑点叉尾鮰(Ictalurus punctatus)体内的残留消除规律。结果显示:血浆中药时数据符合有吸收一室开放模型,动力学方程为:C=3.952660(e-0.027279t-e-0.127279t),吸收半衰期(T1/2kα)为5.4469 h,消除半衰期(T1/2ke)为25.4093 h,达峰时间(Tp)为15.4045 h,达峰浓度(Cmax)为20.3985 mg/L,表观分布容积(Vd)为2.5763(mg/kg)/(mg/L)。肌肉、肝、肾中吸收半衰期(T1/2kα)分别为3.5582、4.1884、5.4397 h,消除半衰期(T1/2ke)为50.8081、23.3504、23.7242 h,达峰时间(Tp)为14.6766、12.6524、14.9967 h,达峰浓度(Cmax)为7.6449、22.9249、40.6047 mg/L,表观分布容积(Vd)为8.5657、2.3970、1.2712(mg/kg)/(mg/L)。结果表明:药物在体内吸收迅速,药物浓度较高,分布广泛,消除较为缓慢。以80 mg/kg剂量混饲口灌3 d后,各组织中三聚氰胺含量总体呈现肾脏>肝脏>肌肉。停止灌药后第5天肌肉中及第7天肝脏和肾脏组织中三聚氰胺含量低于我国(2008)卫生部公布的乳制品及含乳食品中三聚氰胺临时管理限量值和欧盟对中国进口产品设定了三聚氰胺的最大残留限2.5 mg/kg。     

中药诃子的主要成分没食子酸在异育银鲫体内药物代谢动力学研究

在(20±1)℃的水温条件下,以77 mg/kg的单剂量,给异育银鲫(Carassius auratus gibelio)口灌诃子(Fructus chebulae)水剂,以诃子中的主要成分没食子酸为检测目标,用高效液相色谱法(HPLC)检测给药后各个时间点的血药浓度。结果显示:最低检测限为0.01μg/mL,线性范围为0.01～84.00μg/mL。诃子在异育银鲫体内的药动学过程符合一级吸收二室开放房室模型(1/C/C),其药物动力学方程为C=39.237e-0.320t+4.814e-0.006t,主要药动学参数为:吸收速率常数(Ka)为0.56 h-1,吸收半衰期(t1/2ka)为1.238 h,分布半衰期(t1/2α)为2.164 h,消除半衰期为(t1/2β)为119.369 h,达峰时间(Tmax)为4 h,最大血药浓度(Cmax)为11.024μg/mL,血药浓度-时间曲线下面积(AUC(0-∞))=674.89μg.h/mL,延滞时间(TL)为0.286 h,药物平均滞留时间(MRT(0-∞))=113.626 h,总体消除率(CLs)为0.112 L/(kg.h),表观分布容积(Vd)为13.713 L/kg。这些参数表明,异育银鲫口灌诃子后,能比较迅速被吸收,并且在血浆中维持较长的时间,具有较好的应用价值基础。     

Study on the pharmacokinetics of enrofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis, after different administration regimes

A pharmacokinetic study on enrofloxacin (ENR) following different administration regimes (i.e. intramuscular, oral and bath administrations) was carried out for the Chinese mitten-handed crab ( Eriocheir sinensis ) at 17 °C water temperature. Muscle and hepatopancreas samples were collected at each sampling time of 1 and 10 min and 0.5, 1, 2, 8, 16, 24, 48, 72 and 168 h for intramuscular administration and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 h for oral and bath administration. The levels of ENR and ciprofloxacin (CIP) were simultaneously determined ( n =5) by high-performance liquid chromatography. The results showed that similar absorption and elimination patterns of ENR level in muscle and hepatopancreas were observed for oral administration and bath treatment; however, the trend in ENR level changes in muscle and hepatopancreas after intramuscular administration was quite different from oral and bath treatments. Meanwhile, the level of ENR in hepatopancreas was much higher than that in muscle for the same administration regimes. The concentration–time data were analysed with the Practical Pharmacokinetics Program (3P97), and the kinetic profiles of ENR in the hepatopancreas and muscle conformed to two-compartment models. The absorption and elimination of ENR in hepatopancreas for bath treatment were faster than those for oral and intramuscular administrations. However, the pattern was quite different in muscle. The fastest absorption and elimination of ENR in muscle were seen for intramuscular administration.     

Pharmacokinetics of oxolinic acid in gilthead sea bream, Sparus aurata L.

This is the first study on the pharmacokinetic parameters of oxolinic acid (OA) in gilthead sea bream, Sparus aurata L. The kinetic profile of OA was studied after a single intravascular injection (20 mg kg⁻¹) in 100 g fish at 20 °C. The distribution half-life ( t _1/2α) and the elimination half-life ( t _1/2β) of the drug were found to be short (0.51 and 12.60 h, respectively). The drug penetration from the plasma to the tissues was adequate as the apparent volume of distribution of the drug at steady-state ( V _d(ss)) was found to be 2.11 L kg⁻¹. The mean residence time ( MRT ) of OA was short (14.25 h) and the total clearance rate ( Cl _T) of the drug was low (0.15 L kg⁻¹ h⁻¹). The bioavailability ( F %) of OA following oral administration (30 mg kg⁻¹) was also low (14%). Maximum values were observed for muscle at 0.5 h after injection, with levels declining as with subsequent sampling. At the first two time points (0.5 and 1 h) plasma levels of OA were higher than muscle, however, the reverse was evident for subsequent samples. Following oral administration, highest muscle levels were found at 16 h and, with the exception of the 24-h sampling, muscle OA concentrations were higher than plasma at all time points. The fast elimination of OA suggests short withdrawal times with reference to human consumption of treated fish.     

Pharmacokinetics,optimal dosages and withdrawal time of florfenicol in Asian seabass (Lates calcarifer) after oral administration via medicated feed

Asian seabass (Lates calcarifer) is an economically important fish in Asian and Australian markets, but few pharmacokinetic (PK) data of antimicrobial drugs in this species is available. The present study investigated the PK behaviour of florfenicol (FF) through medicated feed in Asian seabass cultured at 25°C. The serum and muscle/skin concentrations of FF and its metabolite florfenicol amine (FFA) were determined by the HPLC-FLD method and analysed by one-compartmental model. The optimal dosages were determined by pharmacokinetic-pharmacodynamic (PK-PD) approach and the linear regression analysis was used to determine the withdrawal time (WDT). The PK study following a single oral administration of 15 mg/kg FF via medicated feed revealed that the absorption half-life (t_1/2Ka), elimination half-life (t_1/2K), peak concentration (C_max), area under the concentration-time curve (AUC), volume of distribution (Vd/F) and clearance (CL/F) were 1.47 h, 8.07 h, 8.61 μg/ml, 146.41 h·μg/ml, 1.19 L/kg and 0.102 L/kg/h, respectively. The muscle/skin concentration-time profile was similar to that of the serum, suggesting well distribution but only a small fraction of FF was metabolized to FFA. The optimal dosage for a minimum inhibitory concentration of 2 μg/ml was calculated as 13.38 mg/kg/day. The appropriate WDT after multiple oral medications with 15 mg/kg FF once daily for 7 days was determined as 8 days. Information obtained from the current study can potentially be applied for the treatment of bacterial diseases in farming Asian seabass.